Therma Bright Reviews Manufacturing Strategy in Light of US Tariff Changes
MWN-AI** Summary
Therma Bright Inc. is actively adapting its manufacturing strategy in response to recent US tariff changes impacting products made in China, particularly its Venowave device. With tariffs threatening to inflate costs for US consumers, the company is undertaking a thorough reassessment of its manufacturing options to maintain competitiveness and stability in its supply chain.
In its review, Therma Bright is exploring multiple strategies, including onshoring manufacturing to North America (Canada, the US, or Mexico) and the possibility of a hybrid model—continuing some operations in China while shifting certain components or processes closer to the US market. The goal is to reduce tariff-related expenses while ensuring product availability and cost-effectiveness.
The company is focusing on several critical aspects in its analysis: supply chain resilience to minimize disruption risks; lead times for production and delivery; quality control to maintain product standards across various manufacturing sites; and intellectual property protection to safeguard against potential infringements. Furthermore, logistics will be assessed for efficiency and transportation costs from different manufacturing locations to the US. Evaluating the long-term geopolitical implications of manufacturing choices is also a priority.
Therma Bright emphasizes that no final decisions have yet been made, and it remains committed to transparency with shareholders throughout the process. The company is poised to provide further updates after completing its comprehensive review.
In conjunction with examining its manufacturing strategy, Therma Bright is also working with national distributors to expand the market presence of Venowave, which is a compact medical device designed to enhance venous and lymphatic flow, making up part of its larger commitment to innovative healthcare solutions.
MWN-AI** Analysis
In light of recent and evolving U.S. tariff policies, Therma Bright Inc. (TSXV: THRM) faces critical decisions regarding its manufacturing strategy, particularly for its Venowave device currently produced in China. The company's proactive approach to reviewing its options and potential strategies reflects a keen awareness of the changing landscape that could impact its market competitiveness and operational costs.
Given the rise in tariffs on foreign goods, especially from China, Therma Bright's exploration of onshoring manufacturing to North America, including Canada, the U.S., or Mexico, is a prudent step. This shift could mitigate tariffs and minimize supply chain disruptions, fostering a more resilient operational framework. Implementing a hybrid model – retaining some Chinese manufacturing while enhancing capabilities in North America – may balance cost efficiency with risk management, allowing for flexible responses to future tariffs or geopolitical tensions.
Investors should keep a close eye on the decision-making process regarding geographic manufacturing location selections. The factors under consideration, including supply chain resilience, lead times, quality control, intellectual property protection, and logistics costs, are crucial for maintaining the quality and accessibility of the Venowave device. The emphasis on thorough risk assessment demonstrates Therma Bright's commitment to navigating current uncertainties with a strategic mindset.
Moreover, maintaining relationships with national distributors and expanding market reach for Venowave is vital amid these changes. Given the device's qualification for Medicare and Medicaid reimbursement, any manufacturing disruptions could significantly impact sales and revenue.
In conclusion, strong management of the manufacturing strategy in response to U.S. tariff changes is essential. Investors should remain engaged and informed, as the company’s tactical choices will likely influence its market positioning and long-term sustainability. A further update on Therma Bright's comprehensive review will be crucial for assessing its future trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update to address the potential impact of recent and evolving US tariff policies on our current manufacturing operations of Venowave in China, which serves the US market.
The Company is actively reviewing the implications of recent tariff changes imposed by the US on goods manufactured in foreign countries, particularly China. These tariffs have the potential to significantly increase the cost of our products sold in the US market. In response, Therma has initiated a comprehensive review of all available manufacturing options to ensure the long-term competitiveness and stability of our supply chain.
Therma is reviewing various manufacturing options which includes a thorough analysis of onshoring and establishing manufacturing capabilities within North America (Canada, USA, or Mexico).
The Company is also considering a hybrid approach; combining manufacturing of Venowave or component parts in China with onshoring in North America. In the case of continued full manufacturing of Venowave in China the option will be evaluated in conjunction with strategies to mitigate tariff costs, including potential absorption of some or all tariff expenses if financially feasible in the current dynamic environment.
The Company's decision-making process will extend beyond pure cost considerations and will encompass critical factors such as:
- Supply chain resilience: assessing the stability and reliability of different manufacturing locations and potential risks.
- Lead Times: evaluating the impact on production and delivery timelines.
- Quality Control: ensuring consistent product quality across different manufacturing environments.
- Intellectual Property Protection: considering the risks associated with different manufacturing locations.
- Logistics and Transportation: analysing the efficiency and cost of moving goods from various manufacturing sites to the US market.
- Market Access and Geopolitical Stability: evaluating the long-term implications of manufacturing locations on market access and geopolitical risks.
Therma Bright recognizes that the current tariff landscape is subject to change. Our analysis will consider various potential scenarios and their impact on our business.
It is important to emphasize that no final decision regarding our future manufacturing strategy has been made at this time. The Company is committed to keeping our shareholders informed. We will provide a further update once our comprehensive review is complete and a definitive course of action has been determined. We appreciate our shareholders' understanding as we navigate this evolving situation and work to ensure the long-term success of the Company.
Therma Bright would also like to announce that it continues to work with national distributors to expand the market presence for Venowave with further updates in the near future.
The Venowave VW5, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is a compact, battery-operated peristaltic pump designed to enhance vascular and lymphatic flow in the lower limbs. When strapped below the knee, the device generates a wave-form motion that compresses the calf, promoting upward displacement of venous and lymphatic fluid. Powered by a single rechargeable 1.5V NiMH AA battery, the FDA-designated Durable Medical Equipment (DME) device allows users to receive treatment while staying active. The Venowave VW5 is built for durability and supports repeated use across multiple patients.
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as manufacturing and future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248674
FAQ**
How will the evolving US tariff policies impact Therma Bright Inc. THRM:CC's manufacturing costs and pricing strategy in the US market?
What specific criteria will Therma Bright Inc. THRM:CC use in evaluating potential manufacturing locations within North America?
How does Therma Bright Inc. THRM:CC plan to ensure the quality and consistency of its Venowave product while considering hybrid manufacturing options?
What are the potential risks that Therma Bright Inc. THRM:CC identifies in terms of supply chain resilience and geopolitical stability related to its manufacturing operations?
**MWN-AI FAQ is based on asking OpenAI questions about Therma Bright Inc. (TSXVC: THRM:CC).
NASDAQ: THRM:CC
THRM:CC Trading
-2.78% G/L:
$0.175 Last:
379,113 Volume:
$0.175 Open:
